Pfizer
NEWS
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.
A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the COVID-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.
According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
Pfizer says it expects the U.S. CDC’s ACI to meet in October to recommend the appropriate and safe use of pneumococcal vaccines, including PREVNAR 20, in adults.
On June 5, the world marks the 40th anniversary of the HIV epidemic. Biopharma researchers continue to develop safe and effective treatments with an eye to a potential cure.
Importantly, the researchers recovered virus that they were able to culture, indicating a high risk for transmissibility.
JOBS
IN THE PRESS